Wilson Martin 4

What Happened
Wilson Martin, General Counsel of Rocket Pharmaceuticals (RCKT), received two equity awards on February 11, 2026: 311,813 restricted stock units (RSUs) granted at $0.00 per share, and a derivative award representing the right to purchase 468,187 shares (option-style award) reported at $0.00. These are grants/awards (not open-market purchases or sales) so there was no cash paid by the insider at grant.

Key Details

• Transaction date: 2026-02-11; Form filed: 2026-02-13 (appears timely, within the typical 2-business-day Form 4 window).
• RSUs: 311,813 units granted at $0.00 (convert one-for-one to common stock per footnote).
• Derivative/Option award: right to purchase 468,187 shares, reported as acquired at $0.00.
• Vesting (per footnotes): one-third vests/ becomes exercisable on Feb 11, 2027; the remaining two-thirds vest in equal quarterly installments over the following two years, subject to continued employment.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing notes: No indication of a 10b5-1 plan, tax-withholding sell, or late filing in the provided details.

Context

• These entries are grants (awards) rather than purchases or exercises: RSUs convert to shares when they vest; the derivative entry is an option-like award that vests over time and gives the right to buy shares later.
• Grants to executives are common as compensation and do not, by themselves, indicate immediate buying or selling intent. They are subject to the company’s vesting and employment conditions.